

ASX Announcement

Data from large animal study shows RECCE® 327 well tolerated

SYDNEY, Australia - 27 March 2017: Recce Limited (ASX: RCE), a pre-clinical-stage pharmaceutical company engaged in the development of a new class of synthetic antibiotic, today released results from an independent study of its lead compound in large animals which showed the company's lead asset RECCE® 327 was well tolerated with no adverse events.

The independent report stated, "There were no adverse clinical signs and no apparent test article-related effects on body weight and blood pressure noted during the study. In conclusion, the intravenous infusion of RECCE® 327 at 70 mg/Kg over four hours was well tolerated."

Recce Limited Executive Chairman Graham Melrose said, "We are encouraged by the promising results and our pre-clinical studies will now focus on intravenous infusion of RECCE® 327 which is being developed initially as a potential treatment for antibiotic resistant sepsis."

The study dosed two dogs with saline (control) and three with RECCE® 327 at 70 mg/kg, respectively, by intravenous infusion over 4 hours (+/- 15 min); 70 mg/kg was chosen as pre-clinical data has indicated that dose is efficacious in mice against Gram-positive or Gram-negative bacteria.

The researchers observed no substantial adverse clinical signs with "lymphopenia and neutrophilia, consistent with a typical stress leukogram pattern, likely due to the test article. No other biologically relevant changes in clinical pathology parameters were noted during the study."

Blood samples for evaluation of haematology, coagulation and clinical chemistry parameters were collected from all dogs prior to treatment initiation, at the end of



ASX: RCE

Head Office - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899
Sydney Office Level 34, 50 Bridge Street, AMP Centre, SYDNEY NSW 2000 **T** +61 (0)2 8216 0768 **F** +61 (0)2 8216 0701
Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

treatment and the following day. The research was conducted in the US by an independent contract research organisation.

About Recce Ltd

Recce Ltd (ASX: RCE) is a world-leader in synthetic-polymer compounds, particularly against all bacteria, and viruses. The RECCE® polymers have been synthesized by an extremely economic method. RECCE® polymers have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327. Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies, and potential financial returns, from manufacture and distribution of its products in about 80% of the world's pharmaceutical markets for antibiotics.

To receive the latest information on Recce - [Subscribe here](#)

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: (08) 9253 9800

Media (Australia)

Andrew Geddes
CityPR
Tel: (02) 9267 4511

Media (International)

Sue Charles/Daniel Gooch
Instinctif Partners
Tel: +44 (0)20 7866 7905
E: recce@instinctif.com

